MDL 100173: (S)-isomer is MDL 100173; (R)-isomer is MDL 101628; RN refers to (4S-(4alpha,7alpha(R*),12bbeta)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 133986 |
| SCHEMBL ID | 8358735 |
| MeSH ID | M0227345 |
| Synonym |
|---|
| pyrido(2,1-a)(2)benzazepine-4-carboxylic acid, 1,2,3,4,6,7,8,12b-octahydro-7-((2-mercapto-1-oxo-3-phenylpropyl)amino)-6-oxo-, (4s-(4alpha,7alpha(r*),12bbeta))- |
| mdl-100,173 |
| mdl 100,173 |
| 142695-09-8 |
| (4s-(4alpha,7alpha(r*),12bbeta))-1,2,3,4,6,7,8,12b-octahydro-7-((2-mercapto-1-oxo-3-phenylpropyl)amino)-6-oxopyrido(2,1-a)(2)benzazepine-4-carboxylic acid |
| mdl 100173 |
| (4s,7s,12br)-6-oxo-7-[[(2s)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,12b-hexahydro-1h-pyrido[2,1-a][2]benzazepine-4-carboxylic acid |
| SCHEMBL8358735 |
| DTXSID70162129 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic data were obtained from 12 young (ages 18-45 years, 10 male, 2 female) and 12 elderly (ages 65-85 years, 7 male, 5 female) healthy subjects in a parallel-group, open-label study." | ( Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers. Argenti, R; Emmons, GT; Jensen, BK; Martin, LL; Martin, NE, 2004) | 0.32 |
| " Serial plasma concentrations of M100240 and MDL 100,173 were analyzed, and pharmacokinetic parameters were calculated with noncompartmental methods." | ( The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240. Barrett, JS; Brennan, B; Cirillo, I; Martin, NE, 2004) | 0.32 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "We predicted M100240 is likely to be well absorbed via passive diffusion across the human gastrointestinal tract following oral administration." | ( Permeation prediction of M100240 using the parallel artificial membrane permeability assay. Hwang, KK; Jiang, L; Martin, NE; Zhu, C, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.99) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||